Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BerGenBio ASA ( (BRRGF) ) has shared an announcement.
BerGenBio ASA has announced the approval of a merger plan with Oncoinvent ASA and BerGenBio Norge AS, following an extraordinary general meeting. This merger, which involves a NOK 130 million rights issue, is expected to enhance the company’s market position in the biotechnology industry, pending customary conditions and regulatory approvals.
The most recent analyst rating on (BRRGF) stock is a Buy with a NOK38.00 price target. To see the full list of analyst forecasts on BerGenBio ASA stock, see the BRRGF Stock Forecast page.
More about BerGenBio ASA
BerGenBio ASA is a biotechnology company focused on developing innovative drugs for aggressive diseases, primarily targeting cancer treatment. The company is known for its research and development in the field of oncology, aiming to address unmet medical needs in the market.
YTD Price Performance: -85.80%
Average Trading Volume: 339,364
Current Market Cap: NOK45.42M
Find detailed analytics on BRRGF stock on TipRanks’ Stock Analysis page.